Volume 8, Number 8; July 18, 2007

Patient:

Session Handout:

Readings:

<4>

Unique Identifier [PMID]: 12527569

Authors: Beckles MA. Spiro SG. Colice GL. Rudd RM.

Institution: Department of Respiratory Medicine, Royal Free Hospital, London, UK.

Title: Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. [Review] [54 refs]

Source: Chest. 123(1 Suppl):97S-104S, 2003 Jan.

Abstract: This chapter describes the components of the initial evaluation for a patient either suspected or known to have lung cancer. The components of the initial evaluation are based on the recognized manifestations of localized lung cancer, ie, symptoms referable to the primary tumor, intrathoracic spread of lung cancer, and patterns of metastatic dissemination. Features of the history and physical signs may be useful indicators of the extent of disease. A standardized evaluation, relying on symptoms, signs, and routinely available laboratory tests, can serve as a useful screen for metastatic disease. Also described are the common features of the various paraneoplastic syndromes associated with lung cancer. [References: 54]

Publication Type: Journal Article. Review.

<8>

Unique Identifier [PMID]: 8474272

Authors: Patel AM. Davila DG. Peters SG.

Institution: Division of Thoracic Diseases and Internal Medicine, Mayo Clinic, Rochester, MN 55905.

Title: Paraneoplastic syndromes associated with lung cancer.[see comment]. [Review] [130 refs]

Source: Mayo Clinic Proceedings. 68(3):278-87, 1993 Mar.

Abstract: Paraneoplastic phenomena associated with primary lung cancer have diverse initial manifestations and epitomize the systemic nature of human malignant disease. The spectrum of clinical features in patients with paraneoplastic syndromes ranges from mild systemic or cutaneous disease to hypercoagulability and severe neuromyopathic disorders. Although the diagnosis is often one of exclusion, an improved understanding of the pathogenesis involved in some of these syndromes has provided another means of recognizing the disorders and perhaps treating the affected patients. Proposed mechanisms of paraneoplastic processes include the aberrant release of humoral mediators such as hormones and hormone-like peptides, cytokines, and antibodies. In this update, we review the potential mechanisms, diagnosis, and treatment of paraneoplastic syndromes associated with lung cancer. [References: 130]

Publication Type: Journal Article. Review.

Resident Report / Department of Medicine & Grady Branch Library

Emory University School of Medicine

2007 Edition

Participating Faculty:  Carlos Del Rio MD  / Joyce Doyle MD / Lorenzo Difrancesco MD / Rachel Del Favero MD / Lewis Satterwhite  MD

Contact: Karl Woodworth